Cancer specific deaths number | Controls number | OR (95% CI) | P | OR (95% CI) | P | |
---|---|---|---|---|---|---|
ACEI user versus non user | ARB user versus non user | |||||
Breast cancer | ||||||
Main analysis: diagnosis to six months prior to deatha | 648 | 3,193 | 0.83 (0.63, 1.09) | 0.18 | 0.94 (0.65, 1.37) | 0.75 |
Diagnosis to 1 year prior to deathb | 583 | 2,875 | 0.87 (0.65, 1.16) | 0.33 | 0.87 (0.58, 1.30) | 0.49 |
Restricted to users of any antihypertensive medicationc prior to cancer diagnosisd | 212 | 994 | 0.87 (0.60, 1.25) | 0.44 | 1.36 (0.85, 2.16) | 0.20 |
Comparison group restricted to users of any antihypertensive in exposure periodc | 361 | 1,624 | 0.79 (0.59, 1.05) | 0.10 | 0.92 (0.63, 1.34) | 0.67 |
Additionally adjusting for other antihypertensivese | 648 | 3,193 | 0.79 (0.60, 1.06) | 0.12 | 0.90 (0.61, 1.33) | 0.60 |
Additionally adjusting for hormone therapy any time after diagnosisf | 648 | 3,193 | 0.80 (0.60, 1.05) | 0.11 | 0.98 (0.66, 1.44) | 0.91 |
≥730 DDDs versus 0 DDDs (non-user) | 648 | 3,193 | 1.06 (0.74, 1.52) | 0.75 | 0.99 (0.64, 1.52) | 0.95 |
Restricted to cancer registries with stage data available for over 85% of patients | 487 | 1,911 | 0.84 (0.59, 1.18) | 0.31 | 1.33 (0.81, 2.17) | 0.25 |
Stage 1 and 2g | 469 | 2,313 | 0.95 (0.68, 1.32) | 0.75 | 1.14 (0.73, 1.81) | 0.56 |
Stage 3 and 4g | 161 | 531 | 0.83 (0.46, 1.51) | 0.54 | 2.37 (1.05, 5.35) | 0.04 |
Pre-diagnostic useh | 695 | 3,413 | 0.86 (0.61, 1.20) | 0.37 | 1.06 (0.65, 1.72) | 0.82 |
Time varying covariate analysisi | 656 | 4,164 | ||||
≥1 DDDs versus 0 DDDs (non-user) | 0.97 (0.77, 1.21) | 0.76 | 1.20 (0.89, 1.62) | 0.23 | ||
1to 365 DDDs versus 0 DDDs (non-user) | 0.90 (0.65, 1.25) | 0.52 | 0.94 (0.55, 1.60) | 0.81 | ||
≥365 DDDs versus 0 DDDs (non-user) | 1.01 (0.77, 1.32) | 0.93 | 1.35 (0.96, 1.91) | 0.09 |